HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

We compared safety and immunogenicity of intradermal (ID) vaccination with and without electroporation (EP) in a phase I randomized placebo-controlled trial of an HIV-DNA prime HIV-MVA boost vaccine in healthy Swedish volunteers.HIV-DNA plasmids encoding HIV-1 genes gp160 subtypes A, B and C; Rev B;...

Full description

Bibliographic Details
Main Authors:	Charlotta Nilsson, Bo Hejdeman, Karina Godoy-Ramirez, Teghesti Tecleab, Gabriella Scarlatti, Andreas Bråve, Patricia L Earl, Richard R Stout, Merlin L Robb, Robin J Shattock, Gunnel Biberfeld, Eric Sandström, Britta Wahren
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4486388?pdf=render

Similar Items

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
by: Biberfeld G, et al.
Published: (2009-10-01)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
by: Wahren B, et al.
Published: (2009-10-01)

P19-29. Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal <it>in vivo </it>electroporation
by: Nihlmark K, et al.
Published: (2009-10-01)

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
by: Patricia J Munseri, et al.
Published: (2015-01-01)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
by: Agricola Joachim, et al.
Published: (2020-11-01)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
by: Joachim A, et al.
Published: (2012-09-01)

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
by: Agricola Joachim, et al.
Published: (2015-01-01)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
by: Biberfeldt Gunnel, et al.
Published: (2006-12-01)

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
by: Agricola Joachim, et al.
Published: (2020-04-01)

DNA/MVA Vaccines for HIV/AIDS
by: Smita S. Iyer, et al.
Published: (2014-02-01)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
by: Edna O Viegas, et al.
Published: (2018-01-01)

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
by: Frank Msafiri, et al.
Published: (2020-11-01)

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
by: Agricola Joachim, et al.
Published: (2016-01-01)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
by: Munseri P, et al.
Published: (2012-09-01)

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
by: Srilatha Edupuganti, et al.
Published: (2020-12-01)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
by: Podola L, et al.
Published: (2012-09-01)

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques
by: Biliana Todorova, et al.
Published: (2017-06-01)

Immunotherapy with an HIV-DNA Vaccine in Children and Adults
by: Paolo Palma, et al.
Published: (2014-07-01)

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV
by: J Hinkula, et al.
Published: (2017-06-01)

Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment.
by: Anna-Karin Roos, et al.
Published: (2009-01-01)

Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor
by: Alessia Lamolinara, et al.
Published: (2015-01-01)

Mapping of SIVmac T-cell epitopes in cynomolgus macaques immunized with auxo-GTU-MultiSIV DNA by the intradermal route followed by electroporation
by: Corneau A, et al.
Published: (2012-09-01)

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
by: Sandhya Vasan, et al.
Published: (2011-01-01)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
by: Mann JF, et al.
Published: (2012-09-01)

Clinical evaluation of a candidate HIV-1 Clade A DNA/MVA vaccine designed for Kenya
by: Mwau, Matilu
Published: (2004)

The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART
by: G. Haidari, et al.
Published: (2019-12-01)

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.
by: Paul F McKay, et al.
Published: (2014-01-01)

Improving the Repeatability and Efficacy of Intradermal Electroporated Self-Replicating mRNA
by: Hanne Huysmans, et al.
Published: (2019-09-01)

Intradermal electroporation of naked replicon RNA elicits strong immune responses.
by: Daniel X Johansson, et al.
Published: (2012-01-01)

P17-11. HIV DNA vaccine delivery in association with electroporation in the skin of nonhuman primates
by: Le Grand R, et al.
Published: (2009-10-01)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
by: McKay PF, et al.
Published: (2012-09-01)

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.
by: Susan Zolla-Pazner, et al.
Published: (2013-01-01)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

Packaging DNA for delivery to cells by electroporation
by: Coulberson, Arlena
Published: (2006)

Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania.
by: Edith A M Tarimo, et al.
Published: (2014-01-01)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

Adventitious Viral Genomes in Vaccines but Not in Vaccinees
by: Robin A. Weiss
Published: (2001-02-01)

Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
by: Godfrey A Dzhivhuho, et al.
Published: (2018-07-01)

Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
by: Sanjay Mehendale, et al.
Published: (2013-01-01)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
by: Beatriz Perdiguero, et al.
Published: (2018-08-01)